However, newer derivatives are being developed to act as dual agonists of both PPARα and PPARγ, offering potential benefits in treating conditions such as obesity and diabetic cardiomyopathy. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.